“…Similarly to the present study, previous studies have estimated the prevalence of NHP use among rheumatology patients as approximately 60%, which is much higher than that of the general population (Alaaeddine, Okais, Ballane, & Baddoura, ; Bruno & Ellis, ; Buchbinder et al, ; Kim & Seo, ; Singh & Levine, ; Tropmann, Johns, & Gray‐Donald, ). We further characterized the proportion of patients taking s‐NHPs, specifically, to be 36%.…”